Previous close | 112.76 |
Open | 109.14 |
Bid | 111.52 x N/A |
Ask | 111.68 x N/A |
Day's range | 103.74 - 113.86 |
52-week range | 81.00 - 115.52 |
Volume | |
Avg. volume | 25 |
Market cap | N/A |
Beta (5Y monthly) | 0.58 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
STAMFORD, CT, September 17, 2024--Vectura Fertin Pharma, Inc., an affiliate of Philip Morris International Inc. (PMI) (NYSE: PM), today announces the sale of its subsidiary Vectura Group Ltd. (Vectura) to Molex Asia Holdings Ltd., and the establishment of master service agreements to develop Vectura Fertin Pharma’s inhaled therapeutics proprietary pipeline. Vectura will be operated by Phillips Medisize, a Molex company. The sale includes upfront cash consideration of GBP 150 million, subject to
STAMFORD, CT, September 12, 2024--Regulatory News: The Board of Directors of Philip Morris International Inc. (NYSE: PM) has increased the company’s regular quarterly dividend by 3.8% to an annualized rate of $5.40 per share.
LAUSANNE, Switzerland, September 09, 2024--Philip Morris International Inc. (PMI) (NYSE: PM) today warns about the high levels of contraband and counterfeit cigarettes in the European Union (EU) year over year, with 35.2 billion illicit cigarettes consumed in the region in 2023, accounting for 8.3% of total consumption in the EU, an increase of 0.1 percentage point compared to 2022.